文献速递胸部肿瘤

外周血浆PTGER4 DNA甲基化有助于鉴别肺癌、良性肺结节和COPD患者

DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients.
PubMed 文献 · Eur J Cancer · 2021-03-01

该研究回顾性分析了121例前瞻性收集的血浆样本中SHOX2和PTGER4的甲基化,样本来自肺癌、良性病变和无结节COPD患者。结果显示肺癌患者中PTGER4 DNA高甲基化频率显著高于对照组(p=0.0004),校正肿瘤体积、吸烟状态、年龄和NELSON试验资格后仍显著。结论认为血浆PTGER4甲基化检测可能作为生物标志物支持高风险人群肺癌筛查中的临床决策。

要点

  • 肺癌患者血浆PTGER4 DNA高甲基化频率显著高于对照组(p=0.0004)。
  • 校正肿瘤体积、吸烟状态、年龄和NELSON试验资格后结果仍显著。
  • 血浆PTGER4甲基化可能辅助高风险人群肺癌筛查中的临床决策。

核心结论

  • 血浆DNA中甲基化PTGER4的检测可能作为生物标志物,支持高风险人群肺癌筛查中对肺部病变患者的临床决策。

研究设计与样本

  • 回顾性分析121例前瞻性收集的血浆样本,分为肺癌组(1A)、良性病变组(1B)和无结节COPD组(2),检测SHOX2和PTGER4甲基化。

主要发现

  • 肺癌患者中PTGER4 DNA高甲基化频率显著高于对照组(p=0.0004)。
  • 校正肿瘤体积、吸烟状态、年龄和NELSON试验资格后,PTGER4高甲基化与肺癌的关联仍显著。

临床怎么用

  • 在高风险人群肺癌筛查中,血浆PTGER4甲基化检测可能辅助鉴别肺部病变的良恶性。

局限性

  • 回顾性分析设计,需进一步在前瞻性研究中探索验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/INTRODUCTION: In contrast to patients who present with advanced stage lung cancer and associated poor prognosis, patients with early-stage lung cancer may be candidates for curative treatments. The results of the NELSON lung cancer screening trial are expected to stimulate the development and implementation of a lung cancer screening strategy in most countries. Widespread use of chest computed tomography scans will also result in the detection of solitary pulmonary nodules. Because reliable biomarkers to distinguish between malignant and benign lesions are lacking, tissue-based histopathological diagnostics remain the gold standard. In this study, we aimed to establish a test to assess the predictive ability of DNA hypermethylation of SHOX2 and PTGER4 in plasma to discriminate between patients with 1.) lung cancer, 2.) benign lesions, and 3.) patients with chronic obstructive pulmonary disease (COPD). PATIENTS AND METHODS: We retrospectively analysed SHOX2 and PTGER4 methylation in 121 prospectively collected plasma samples of patients with lung cancer (group 1A), benign lesions (group 1B), and COPD without nodules (group 2). RESULTS: PTGER4 DNA hypermethylation was more frequently observed in patients with lung cancer than in controls (p = 0.0004). Results remained significant after correction for tumour volume, smoking status, age, and eligibility for the NELSON trial. CONCLUSIONS: Detection of methylated PTGER4 in plasma DNA may serve as a biomarker to support clinical decision-making in patients with pulmonary lesions at lung cancer screening in high-risk populations. Further exploration in prospective studies is warranted.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schotten LM, Darwiche K, Seweryn M, et al. DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients. Eur J Cancer. 2021. PMID: 33662689. doi:10.1016/j.ejca.2021.01.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。